Taufon-Darnitsa eye drops solution 4% bottle 10 ml

Instructions Taufon-Darnitsa eye drops solution 4% bottle 10 ml

Composition

active ingredient: taurine;
1 ml of solution contains 40 mg of taurine;
Excipients: methyl parahydroxybenzoate (E 218), water for injections.

Dosage form

Eye drops, solution.
Main physicochemical properties: clear, colorless liquid, odorless.

Pharmacotherapeutic group

Means used in ophthalmology. Other ophthalmological means. ATX code S01X A.

Pharmacological properties

Pharmacodynamics

Taufon-Darnitsa contains taurine - a sulfur-containing amino acid that is formed in the body during the conversion of cysteine. Taurine participates in the synthesis of plastic material, as a result of which it stimulates reparative and regenerative processes in dystrophic eye diseases and/or pathological processes accompanied by a sharp disruption of the metabolism of eye tissues, including eye injuries. It contributes to the normalization of cell membrane functions, optimization of energy and metabolic processes, maintenance of the constancy of the electrolyte composition of the cytoplasm of cells, inhibition of synaptic transmission.

Pharmacokinetics

When instilled, the drug penetrates the eye tissue, where it exerts its specific effect. When used in therapeutic doses, the drug is practically not absorbed into the systemic bloodstream.

Indication

Dystrophic lesions of the cornea and retina, including hereditary tapetoretinal degeneration; cataracts (age-related, diabetic, traumatic, radiation); as a means of stimulating reparative processes in corneal injuries; open-angle glaucoma (as an additional agent).

Contraindication

Hypersensitivity to taurine or to other components of the drug.

Interaction with other medicinal products and other types of interactions

When used together with timolol eye drops, the decrease in intraocular and arterial pressure is enhanced.
When prescribing several topical medications to the eye at the same time, they should be administered at intervals of 10–15 minutes. Eye ointments should be applied last.

Application features

In open-angle glaucoma, the drug should be used in combination with timolol 20–30 minutes before instillation of timolol.
Excipients: the medicinal product contains methyl parahydroxybenzoate (E 218), which may cause allergic reactions (possibly delayed).

Ability to influence reaction speed when driving vehicles or other mechanisms

The effect of the drug on the human body while driving or working with other mechanisms has not been studied.
As with other topical ophthalmic medicinal products, temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs after instillation, the patient should wait until the vision clears before driving or operating machinery.

Use during pregnancy or breastfeeding

The efficacy and safety of the drug during pregnancy or breastfeeding have not been studied.

Method of administration and doses

Taufon is prescribed for adults.
Immediately before use, hold the dropper tube with the medicine in the palm of your hand to warm it to body temperature. To open the dropper tube, turn the cap until it is completely separated from the body. Lightly pressing on the body of the dropper tube, instill the solution into the eye.
For the treatment of cataracts, prescribe 2–3 drops 2–4 times a day every day. Duration of treatment – 3 months. Repeat the course with an interval of 1 month.
For injuries, apply 2–3 drops 2–4 times a day for 1 month.
For the treatment of tapetoretinal degeneration and other degenerative diseases of the retina, penetrating corneal injuries, the drug is administered under the conjunctiva at a dose of 0.3 ml of a 4% solution once a day for 10 days. The course of treatment is repeated after 6–8 months.
In open-angle glaucoma, the drug is instilled 2–3 drops into the conjunctival sac 2 times a day 20–30 minutes before using timolol. The course of treatment is determined by the doctor individually.

Children

The efficacy and safety of the drug in children have not been studied.

Overdose

Cases of overdose have not been described.

Adverse reactions

Some patients may develop allergic reactions, conjunctival hyperemia, itching, burning, and stinging in the eyes.

Expiration date

2 years.
After opening the bottle, store the medicine for no more than 28 days.

Storage conditions

Store in original packaging at a temperature not exceeding 15 °C. Do not freeze. Keep out of the reach of children.

Packaging

10 ml in a bottle; 1 bottle in a pack.

Vacation category

According to the recipe.

Producer

PrJSC "Pharmaceutical Company "Darnitsa".

Ukraine, 02093, Kyiv, Boryspilska St., 13.